|Bid||24.48 x 1100|
|Ask||24.60 x 1100|
|Day's Range||24.37 - 26.69|
|52 Week Range||2.52 - 38.50|
|Beta (5Y Monthly)||4.05|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 09, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||37.50|
Differences in focus, size of holdings, and weightings add to difficulty in choosing the right fund. Why ARK Genomic Revolution and SPDR S&P Biotech ETFs stand out.
Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14 at 11:40 a.m. ET.
Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the publication of data analyses from the Company’s Phase 1b trial of SER-287 in patients with active mild-to-moderate ulcerative colitis (UC), most of whom were failing current therapies. The study results demonstrated that SER-287 administration was associated with positive impacts on clinical remission, endoscopic improvement, modulation of the gastrointestinal microbiome, and a favorable tolerability profile.